Insmed PT Raised to $67 at TD Cowen By beragampengetahuan.com – Beragampengetahuan
TD Cowen analysts raised the price target on Insmed (NASDAQ:) to $67.00 (from $45.00) while maintaining a Buy rating. The analysts commented, “We think this AM’s best case scenario ASPEN data drives 80%+ probability of US, EU and JP approval. Given the clinically meaningful effect size with strong stat significance, along with strong stats and/or […]
Insmed PT Raised to $67 at TD Cowen By beragampengetahuan.com – Beragampengetahuan Read More ยป